Exciting News for Phio Pharmaceuticals Corp.
New Investment Opportunities in the Biotechnology Sector
Phio Pharmaceuticals Corp. Announces Stock Purchase and Sale Agreements
Marlborough, Massachusetts–(Newsfile Corp. – December 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 240,000 shares of its common stock at a purchase price of $2.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 240,000 shares of common stock.
This latest development is a significant milestone for Phio Pharmaceuticals Corp. as it secures funds for further research and development in the field of biotechnology. The purchase and sale agreements demonstrate investor confidence in the company’s innovative approach to developing therapeutics that target cancer cells at the genetic level.
Phio Pharmaceuticals Corp.’s INTASYL® siRNA gene silencing technology has shown promising results in preclinical studies, making the company a frontrunner in the biotechnology sector. With this new investment, Phio Pharmaceuticals Corp. is well-positioned to advance its research and potentially bring new treatments to market that could revolutionize the way cancer is treated.
Impact on Individuals
For individuals, the news of Phio Pharmaceuticals Corp.’s stock purchase and sale agreements presents a unique investment opportunity in the biotechnology sector. Investing in innovative companies like Phio Pharmaceuticals Corp. could not only offer financial returns but also contribute to advancements in healthcare and potentially life-saving treatments for cancer patients.
Global Impact
The advancements made by Phio Pharmaceuticals Corp. in developing therapeutics using INTASYL® siRNA gene silencing technology have the potential to have a global impact on cancer treatment. Targeting cancer cells at the genetic level with more effective immune cells could lead to breakthroughs in personalized medicine and improved outcomes for patients worldwide.
Conclusion
Phio Pharmaceuticals Corp.’s purchase and sale agreements mark an exciting milestone for the company and the biotechnology sector as a whole. The investment and the development of innovative therapies underscore the importance of research and development in advancing healthcare and potentially revolutionizing cancer treatment. Individuals interested in investing in the biotechnology sector should consider the opportunities presented by companies like Phio Pharmaceuticals Corp., while globally, the potential impact of these advancements in cancer treatment is immense.
